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Microbes rarely exist in isolation, rather, they form intricate multi-species com-
munities that colonise our bodies and inserted medical devices. However, the
efficacy of antimicrobials is measured in clinical laboratories exclusively using
microbial monocultures. Here, to determine how multi-species interactions me-
diate selection for resistance during antibiotic treatment, particularly following
drug withdrawal, we study a laboratory community consisting of two microbial
pathogens. Single-species dose responses are a poor predictor of community
dynamics during treatment so, to better understand those dynamics, we in-
troduce the concept of a dose-response mosaic, a multi-dimensional map that
indicates how species’ abundance is affected by changes in abiotic conditions.
We study the dose response mosaic of a two-species community possessing
a ‘Gene×Gene×Environment×Environment’ ecological interaction whereby Can-
dida glabrata, which is resistant to the antifungal drug fluconazole, competes for
survival with Candida albicans, which is susceptible to fluconazole. The mosaic
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comprises several zones that delineate abiotic conditions where each species dom-
inates. Zones are separated by loci of bifurcations and tipping points that identify
what environmental changes can trigger the loss of either species. Observations
of the laboratory communities corroborated theory, showing that changes in both
antibiotic concentration and nutrient availability can push populations beyond tip-
ping points, thus creating irreversible shifts in community composition from drug
sensitive to drug resistant species. This has an important consequence: resis-
tant species can increase in frequency even if an antibiotic is withdrawn because,
unwittingly, a tipping point was passed during treatment.
Antimicrobial resistance poses a formidable challenge for medicine with resistance to all but the
most recently discovered antibiotics encountered in clinical and agricultural practice (1). Seeking
behavioural changes in antibiotic prescription to control resistance is a field of active theoretical,
laboratory and clinical research. Importantly, it has been mooted that resistance could be eliminated
using evolution-aware strategies that reverse the arrow of time (2). But is drug resistance reversible?
And if not, why not?
Antibiotic cycling, whereby different antibiotics are prioritised and restricted through time, can
lead to the reversal of resistance if resistant microbes pay the price for their abilities to resist by having
reduced fitness when drugs are not around (3, 4). This idea has been tested clinically, with mixed
outcomes. Restricting use can reduce resistance (5,6) though not always (7) and, perversely, increases
in resistance have been observed following drug restrictions (6, 8). Thus clinical strategies that
cycle antibiotics have unpredictable effects: they can work (9–13) but sometimes they fail (14, 15).
It is unclear why a self-evidently worthwhile strategy of antibiotic withdrawal would not reduce
resistance. An absence of fitness costs of resistance (16) is one potential explanation but, in microbial
communities, as we now explain, there is another.
Our explanation is this. For simplicity, imagine a microbial community dominated by two species,
S and R. Assume the former is sensitive to an antimicrobial and the latter is resistant. Suppose S
can invade, and displace, R in the absence of drug and R can invade and displace S in the presence
of drug; in this case the drug resistance phenotype of the community is reversible. However, if,
now in a different community, R invades and displaces S in the presence of drug but, in the drug’s
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absence, the community exhibits a frequency dependent bistability (17) whereby either R or S can
dominate, then this community need not have reversible resistance. Here, application of drug forces
R to become dominant and the inability of S to always re-invade following withdrawal could cause
resistance not to reverse. Now a tipping point is said to occur when S can no longer invade and we
provide theoretical mechanisms and microbial data demonstrating how the irreversibility of resistance
can arise through tipping.
Metagenomic analyses are rapidly improving our understanding of microbial communities. We
now know that antibiotics affect communities in load (18) and in diversity (19) and, intriguingly,
the removal of antibiotic sometimes (20, 21) but not always (22, 23) restores the community to its
original, pre-treated composition. However, selection for resistance within communities is poorly
understood because key pharmacological indicators, like the minimal inhibitory concentration (MIC),
dose-responses, between-antibiotic drug interactions and costs of resistance are measured in single-
species assays. These assays ignore the antibiotic’s true context: while microbes can exist as single-
species populations, in bloodstream infections, say, most real-world microbes thrive in communities.
Why, therefore, should a single-species understanding of microbial responses to antibiotics completely
explain resistance progression on the skin, in the gut or a hospital ward?
To support this view, here we show that single-species resistance measures can be poor predic-
tors of resistance in a synthetic microbial community both during treatment, and after antibiotic
withdrawal, because of a hitherto unobserved phenomenon: communities can have tipping points
when abiotic parameters like treatment duration, antibiotic dose and nutrient availability vary. For
example, clinicians vary dosing regimens (24–26) and treatment duration (27) of critically ill pa-
tients while nutrient availability, in the form of glucose concentration, can vary from 0.01 − 0.28%
in urine (28) to 0.1− 2.7% in blood with substantial daily variation (29, 30). The impact of this on
drug resistance is unknown.
We explore resistance and abiotic variation in the simplest possible community of two species,
Candida albicans and Candida glabrata. Both are commensal microbes found together in the micro-
biota of healthy individuals but they are also opportunistic pathogens causing mucosal infections (31)
and life-threatening disseminated infections among immunocompromised patients (32). Difficult to
diagnose, Candida infections are associated with high mortality rates, ranging from 46-75% for Can-
didiasis in the bloodstream (33–35). Strikingly, as many people die each year from the top ten
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invasive fungal diseases, including candidiasis, as do from tuberculosis or malaria (33). Apart from
its substantial impact on human health, our community treatment model is suited to studying drug
withdrawal dynamics because C. glabrata infections are relatively unresponsive to the most frequently
used antifungal drug fluconazole, while C. albicans is sensitive to fluconazole (36). Monoculture dose
response assays demonstrate this for our study strains at clinical doses (Supporting Fig. S2).
We determined temporal dynamics of the Candida species empirically by monitoring their rel-
ative frequencies. For this we co-cultured both in shaken, 96-well plates containing liquid growth
media supplemented with glucose and fluconazole. The plates were inoculated with a mixture of
fluorescently labelled C. albicans, at proportion f , and C. glabrata, at proportion 1 − f . After 24h
of growth (a.k.a. one season) densities and frequencies of each species were determined using flow
cytometry and a fixed volume sample (3.3%) of the community was transferred to a new 96-well
plate containing fresh media, marking the beginning of a new season (Methods).
Applying single-species logic to this community, the resistant species, C. glabrata, should domi-
nate in the presence of enough drug. Indeed, there is evidence this is predictive of clinical outcomes:
the use of fluconazole prophylaxis was found to influence the proportion of C. albicans and C. glabrata
isolated from the blood of patients with candidemia (37), leading to an increase in C. glabrata fre-
quency. Fluconazole withdrawal should then shift the community towards the sensitive species, C.
albicans. Importantly, we can replicate both these observations using our community: under flu-
conazole treatment the drug resistant C. glabrata dominates and when the drug is removed, the
sensitive C. albicans subsequently recovers. This creates a repeatable, cyclical dynamic as the drug
is repeatedly applied and withdrawn (Figure 1(a)).
But is this the only dynamic possible following fluzonazole withdrawal? To answer this we
now systematically explore community dynamics under different abiotic conditions by applying ideas
from microbial population biology (38). Recalling C. albicans are inoculated into the microcosm at
proportion f , suppose F denotes the frequency of C. albicans after one season, so R(f) = F/f
denotes the change in C. albicans relative frequency. Now, F = f ·R(f) is a ‘single-season frequency
change map’ that gives the frequency of C. albicans after one season and we will write F as a
mathematical function, calling it Φ, thus Φ(f) = f ·R(f). Repeated applications of Φ to frequency
values can therefore be used to determine the C. albicans frequency after any number, n ≥ 1, of
seasons, provided a given initial (inoculum) frequency f0 is known. So, f1 = Φ(f0) is the frequency
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of C. albicans after one season, f2 = Φ(Φ(f0)) = Φ(f1) is the frequency of C. albicans after two
seasons, f3 = Φ(Φ(Φ(f0))) = Φ(f2), and so on. In population dynamics theory it is common to
write season number as a subscript n, so fn+1 = Φ(fn) is a shorthand representation of the season-
by-season dynamics at season n. It follows by definition that Φ(0) = 0 because with no C. albicans in
the inoculum, it cannot appear subsequently. Similarly, Φ(1) = 1 must hold as a closed community
containing only C. glabrata initially must always do so (see Supplementary Information 2 for details).
What should a biologically reasonable Φ look like? Figure 1(b) shows four lab-derived exemplars
and we also use a bottom-up mathematical model that builds theoretical Φ functions (Figure 1(c),
Supplementary Information 3). The latter can incorporate many microbial life history traits and
environmental variables but here we focus on antimicrobials (at concentration a) and extracellular
nutrient concentrations, say g denoting the carbon source glucose. We restrict attention for now to
just a, ignoring g dependence, and write Φ(f, a) to emphasise this.
We now ask how the community responds to an antimicrobial by introducing a sequence of
antimicrobial dosages, an, so that fn+1 = Φ(fn, an) where the treatment can change with each
season. In the clinic, an might be one of two extremes, either a high dosage above the drug’s MIC
(minimal inhibitory concentration) or zero when treatment stops. Figure 1(c) shows two theoretically-
constructed Φ functions, Φon and Φoff, motivated by this clinical context:
fn+1 =
{
Φon(fn) : if antimicrobial is applied (so an ≥ MIC),
Φoff(fn) : if antimicrobial is not applied (so an = 0).
Empirical Φ functions (Figure 1(b)) strongly resemble their theoretical counterparts (Figure 1(c))
and, in these figures, both theory and data exhibit reversible resistance.
However, theory-derived Φon and Φoff provide information about when not to expect reversible
resistance (Figure 2(a-d)) and the shape of these two functions is all-important. If Φon satisfies
Φon(f) < f for all f between 0 and 1, then fn+1 = Φon(fn) < fn follows, meaning the frequency
of C. albicans decreases each season when drug is applied (Figure 2(a)). Conversely, if Φoff(f) > f
for all f then C. albicans increases each season after treatment withdrawal, whence resistance is
reversible (Figure 2(b)). Points of separation, or separatrixes, between these two cases arise when
there are frequencies, f , for which Φoff(f) = f (Figure 2(c,d)). As a consequence, for our purposes
a tipping point, fu, satisfies Φoff(fu) = fu and other technicalities (Supplementary Information 2
and 4) . This condition allows either C. albicans or C. glabrata to dominate in the absence of drug
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and, as a result, drug treatment can coerce the microcosm towards either possibility when treatment
stops (Supplementary Information 4).
Using a fixed-glucose stochastic model fn+1 = Φ(fn, an) + σn, where σn is small-variance noise
and the form of Φ is defined in Supplementary Information 3, we show that resistance need not
be reversible because a tipping point is encountered in a theoretical 4-day treatment (Figure 2(f-
g)) that is not encountered if treatment terminates at 3 days (Figure 2(e)). Figure 2(h,i) then
incorporates glucose dependence, g, and explores a model Φ(f, a, g) in different abiotic conditions
by systematically varying g and antibiotic dose, a (Supplementary Information 3.2 and 4). This is
impossible to do in empirical microbial ecologies but computational simulations (Figure 2(h)) show
the dominant Candida species, albicans or glabrata or neither, in the (a, g)-plane (this is the ‘dose-
response mosaic’). This computational analysis shows the dosage at which tipping occurs depends
on glucose availability and we will therefore now also manipulate glucose availability in our empirical
microcosm.
So does the laboratory treatment community also possess tipping points when antibiotic dose
or else glucose availability vary? This is difficult to assess directly for several reasons. First, our
modelling framework is general but simple and so is not able to accurately pinpoint tipping points in
an empirical context. Second, theoretical tipping mechanisms require an unstable fixed point (fu)
under drug-free conditions. These are hard to identify empirically because observations move away
from unstable fixed points and so these points, if present, cannot be detected directly in longitudinal
data, we can only infer their presence. Other warning signals of tipping exist (39, 40) for example
so-called ‘critical slowing down’ (41, 42), slow recovery from perturbations (43, 44), an increase in
autocorrelation (45), an increase in the variation of fluctuations (46,47) or timeseries skewness (48).
We therefore chose variance increases because modelling indicates between-replicate variance (BRV)
should increase sharply at a tipping point (Figure 3).
We sought antibiotic tipping experimentally for three treatments, α, β and γ that are designed
to explore the dose response mosaic as fully as possible. First, α) glucose is held constant but the
drug steadily withdrawn; β) glucose and drug are held constant and γ) glucose is reduced while the
drug is withdrawn (Figure 4(a)). For these treatments, glucose varied between 0.1 − 4% mirroring
prior in vitro Candida experiments (49, 50) and fluconazole varied between 0 − 3µg/ml, mirroring
prior in vitro drug-adaptation studies (51).
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Treatments α and β lead to reversible resistance (Figure 4(b)) whereby the C. albicans frequen-
cies on the last season have almost unimodally distributed between-replicate variation (BRV) (Figure
4(c)). However, treatment γ exhibits characteristics of tipping: BRV statistics of C. albicans fre-
quencies on the last observed season approximate a uniform distribution (Figure 4(c)) and mean
BRV spikes on season 6 (approximately 8× increase, Figure 4(d,e)). The rapid divergence of repli-
cate trajectories (Figures 4(b), Supporting Fig. S12) that forms a uniform distribution of treatment
outcomes for γ (Figure 4(c)) in a manner consistent with theory (Supporting Fig. S9) means that
many community trajectories have not returned to their inoculum positions, in contrast to reversible
resistance (Figure 1(a)) where they have.
Discussion
The reversibility of resistance is often conceptualised through resistance costs (16), a property which
ensures resistance genes are lost following drug withdrawal due to a fitness reduction of the mutants
that carry them. However the analogy of resistance costs between species is difficult to define.
For example, without the drug in our community the Candida species have different metabolism
(52) from which complex, density and frequency dependent ecological interactions like cheating and
cooperation can result (53). Indeed, the myriad ecological interactions present in natural communities
are necessarily perturbed by an antibiotic drug so a model of resistance progression in which resistant
and susceptible microbes differ by a single allele will have limited explanatory power here. Thus
we invoke tipping as a new mechanism for understanding the dynamics of drug resistance following
exposure to antibiotics.
The explanation behind the tipping-induced irreversibility of resistance is this: if a community
could persist in multiple configurations in the absence of drug (17), antibiotics, indeed, any abiotic
perturbation, might push the community into the ‘basin of attraction’ of the most resistant config-
uration from all those available. So even if treatment stops, resistance species’ frequencies could
increase. Our mathematical models illustrate just two basins of attraction, one above the tipping
point and one below (Figure 3(a)) but real-world communities may well have more.
Unfortunately, the key ingredient for tipping, multi-stability, is known to be difficult to demon-
strate in real communities (17) but if present, we then know the removal of drug can create an
uncertain future for that community. Figure 3(b) and 4(b) show in theory and in data how some
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of those divergent futures pan out; some return whence they came, others move towards a new
configuration of the community. This is the defining property of multistability (17) and if this new
configuration comprises more species that are less susceptible to the drug than were there prior to
treatment, resistance in the community will increase even though treatment has stopped.
Our microcosms highlight just one treatment consistent with this theory (Figure 4) but what
other treatments might do this? Indeed, data show that not all drug treatments induce tipping
(Figure 4). However, mathematics answers the question: any co-variation of abiotic environment
and drug, whether stochastic, cyclical, gradual or abrupt that guides the community into a region
of the dose-response mosaic that exhibits multi-stability (Figure 2(h) grey zone) creates the right
conditions for tipping. Our empirical data provides one example of this (treatment γ) from the
infinitely many treatments we could have tested and the mathematical model we present undergoes
tipping with this type of treatment (Supporting Fig. S9) and for many more besides. The theoretical
treatment examples we provide (Figure 3 and Supporting Fig. S10) illustrate, perhaps, the simplest
possible abiotic variation that can exhibit tipping, namely the abrupt cessation of a constant-dose
drug treatment (Figure 3) of the kind given to patients in the community.
To conclude, we argue that single-species logic is insufficient to understand resistance in microbial
communities. Particularly lacking is a theory of how abiotic variation promotes resistance and yet
this is relevant to patients. For example, infections involving C. glabrata are more frequently found
in diabetic patients with high blood glucose levels than in patients with lower glucose levels (54,55),
indicating that nutrient availability may play a role in clinical resistance, just as it does in our
community. Our observations may also indicate potential for alternative therapeutic rationales for
polymicrobial infections. Diet is known to alter the host microbiota (56–58) and so fashioning
specific environments by manipulating nutrients might tip the balance of competition in favour of
drug-susceptible species and render an infection more amenable to treatment. There is a precedence
for this idea (59–61).
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Methods
Strains and assay medium
The strains Candida albicans ACT1-GFP and Candida glabrata ATCC2001 were used throughout
this paper in all Experimental designs 1 − 3. The strain C. albicans ACT1-GFP strain is SBC153
(62) with pACT1-FLAG-GFP integrated at the ACT1 locus by means of positive selections using a
nourseothricin resistance cassette. The strain C. glabrata ATCC2001 is the wild type reference strain
obtained from the American Type Culture Collection. The assay medium throughout was synthetic
complete (SC) (0.67% w/v yeast nitrogen base without amino acids, 0.079% w/v synthetic complete
supplement mixture (Formedium, Hunstanton, UK)).
Measuring growth of C. albicans and C. glabrata in isolation in the absence / presence
of drugs
Overnight cultures in YPD of C. albicans and C. glabrata were diluted, counted on hemocytometer,
and adjusted to 2 × 107 cells/mL in SC medium containing 2% (weight/volume) glucose. Sterile
plastic microdilution plates containing 96 flat-bottomed wells were utilized. Stock solution of flu-
conazole was diluted in SC medium and dispensed in 75 µL volumes into six replicate wells to yield
nine two-fold serial dilutions of fluconazole with final concentrations ranging between 0− 64 µg/mL.
For each drug concentration, three of the six replicate wells were filled with additional 75 µL from
the C. albicans strain suspension while the remaining three wells were filled with 75 µL from the C.
glabrata strain suspension. The plate was sealed with a transparent adhesive seal and two holes were
punctured over each well by means of a sterile needle. The plate was incubated at 30oC with shaking
over 24 hours and growth monitored by measuring the absorbance of the cell suspensions at 650 nm
(A650). Absorbance units were converted into number of cells per ml by means of calibration curves
prepared for each Candida species.
Drug susceptibility dose-response for C. albicans and C. glabrata
Standard micro-dilution susceptibility testing was performed in sterile 96-well flat-bottom microtiter
plates with the following modifications. Fluconazole was diluted from a 2mg/mL stock solu-
tion to a dilution series ranging from 512 to 0 µg/mL in SC media containing 1% or 4% glucose
(weight/volume), at a volume of 75 µL per well. Overnight cultures in YPD of C. glabrata and
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C. albicans were counted by haemocytometer and diluted to 105 cells/mL in SC broth contain-
ing either 1% or 4% glucose. For each species, 75 µL of cell suspension was added per well, re-
sulting in a final volume of 150 µL which contained 5 × 104 cells, a final drug concentration of
256, 192, 128, 96, 64, 48, 32, 16, 8, 4, 2 or 0 µg/mL of fluconazole and either 1% or 4% glucose. The
plate was sealed with a transparent adhesive seal and two holes were punctured over each well, by
means of a sterile needle, for aeration. Plates were incubated for 48 hours at 30oC after which final
absorbance was measured at A595. All samples were assayed in technical triplicate.
Competition of C. albicans and C. glabrata in the absence/presence of drugs
Overnight cultures in YPD of C. albicans and C. glabrata were diluted, counted on hemocytometer,
and adjusted to 2×107 cells/mL in SC medium containing either 0.1, 2, or 4% (weight/volume) glu-
cose. The two Candida species were then mixed to achieve a range of starting ratios (0, 10, 30, 50, 70, 90
and 100% C. albicans) The cell suspension was then diluted 1:1 in SC media containing two times
desired fluconazole concentration (0, 0.5, or 2 µg/mL) to a final volume of 150 µL in a 96 well flat
bottom microtiter plate. Plates were sealed using sterile adhesive films, two holes were punched in
seal above each well using a sterile needle, and incubated overnight in orbital shaker set at 30oC,
180 rpm. Each condition was repeated in triplicate. After 24 hour incubation period (one season)
plates were opened, the contents of the well were vigorously pipetted to achieve a homogenous cell
suspension, and relative frequency of C. albicans ACT1-GFP was determined by flow cytometry in
the following way (Supporting Fig. S1). Cellular fluorescence from GFP was determined quantita-
tively with a FACSAria flow cytometer (Becton Dickinson, CA, USA) equipped with a 20mW, 488
nm argon ion laser. All samples were suspended in phosphate buffered saline (PBS) and briefly
sonicated to disperse potential cell clumps prior to analysis. Typically, 10000 cells were analysed per
competition sample with the following settings: forward scatter (150 V, log mode) and side scatter
(200 V, log mode). GFP was detected on a 530/30 filter (600 V, log mode) and sample acquisition
was performed using BD FACSDiva software. Initially, a sample consisting of C. albicans ACT1-GFP
cells only was detected and gated to contain 99− 100% of all measured events as positive for GFP
fluorescence. All events occurring within the gate during subsequent analysis of competition samples
were considered to be C. albicans ACT1-GFP cells. For any given competition sample, the frequency
of gated events was calculated by means of FlowJo software and was taken to be the population
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percentage of C. albicans ACT1-GFP within the sample.
Long-term competition of C. albicans and C. glabrata for different drug regimes
Overnight cultures in YPD of C. albicans and C. glabrata were diluted, counted on hemocytometer,
and adjusted a 1:1 ratio of each species, at a final concentrations of 2× 107 cells/mL in SC medium
containing either 0.1, or 4% (weight/volume) glucose. The cell suspension was then diluted 1:1 in SC
media containing two times desired fluconazole concentration (3 µg/mL) and the matching glucose
concentration, to a final volume of 150 µL in a 96 well flat bottom microtiter plate. Plates were
sealed using sterile adhesive films, two holes were punched in seal above each well using a sterile
needle, and incubated overnight in orbital shaker set at 30oC, 180 rpm. Each treatment was repeated
in triplicate. After 24 hour incubation period (one season) plates were opened, the contents of the
well were vigorously pipetted to achieve a homogenous cell suspension, and five microliters of cell
suspension was added to a new well containing 145 µL of SC media which contained either the same,
or a reduced concentration of glucose and fluconazole. Specifically, for treatment α the cultures were
maintained in 0.1% glucose throughout, while the fluconazole concentration was adjusted each season
(3, 2, 1, 0.5, 0 µg/mL). For treatment β the glucose concentration remained at 0.1% and fluconazole
concentration at 0.5 µg/mL throughout the duration of the experiment. Lastly, for treatment γ
both glucose and fluconazole concentrations were reduced each season, glucose decreasing from 4
to 0.1% (4, 2, 1, 0.5, 0.1) and fluconazole decreasing from 3 to 0 µg/mL (3, 2, 1, 0.5, 0). Note that
5µL represents the smallest volume transfer that ensures the accuracy of pipetting is maintained.
The relative frequency of C. albicans was monitored either by flow cytometry or CFUs, as described
above. For daily monitoring 9−12 replicate biological samples were measured, while at the endpoint
all replicates were analysed (48 replicates for treatment α, 96 replicates for treatment β and 55
replicates for treatment γ).
Oscillatory (a repeated on-off) drug treatment
Overnight cultures in YPD of C. albicans and C. glabrata were diluted, counted on hemocytometer,
and adjusted a 1:1 ratio of each species, at a final concentrations of 2× 107 cells/mL in SC medium
containing 0.1% (weight/volume) glucose. The cell suspension was then diluted 1:1 in SC media
containing two times desired fluconazole concentration (0, 2, or 4 µg/mL) to a final volume of
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150 µL in a 96 well flat bottom microtiter plate. Plates were sealed using sterile adhesive films,
two holes were punched in seal above each well using a sterile needle, and incubated overnight
in orbital shaker set at 30oC, 180 rpm. Each condition was repeated in triplicate. After 24 hour
incubation period (one season) plates were opened, the contents of the well were vigorously pipetted
to achieve a homogenous cell suspension, and five microliters of cell suspension was added to a new
well containing 145 µL of SC media which contained the same drug concentration as the day prior, for
three days. At day three through day 14, cells were cultured without drug. On day 14 all conditions
were treated with 2 µg/mL fluconazole for an additional three day (through day 17) at which point
drug was again omitted from culturing through end of experiment. All wells were passaged daily,
on days with data points shown in Figure 1a a volume of suspension was removed for sampling. To
monitor relative frequency of each Candida species, colony forming units (CFU) were enumerated by
plating on YPD agar either with or without the C. albicans strain selection nourseothricin (NAT) at
200 µg/mL. Briefly, cell suspension from overnight culture was diluted to roughly 200 CFU/ 100 µL
and plated on both YPD and YPD+NAT plates, each well was plated in duplicate. Plates were
incubated at 30oC for 48 hours and colonies counted, with the percent C. albicans being determined
by the ratio of NAT resistant cells to total cells on untreated YPD plates.
Intracellular fluconazole accumulation
The accumulation of fluconazole for both C. albicans and C. glabrata was analyzed in energized cells
in the presence of glucose using the protocol described in (63). Cells were incubated with [3H]-FLC
(specific activity 740 GBa/mmol, 20 Ci/mmol, 2× 104 CPM/pmol, 1 µCi/ µL; 50 µM FLC; custom
synthesis by Amersham Biosciences, UK). Cells were grown overnight in CSM complete medium at
30◦C to a density typically between OD600 6.0 to 8.0, unless otherwise noted. Cells were subsequently
harvested by centrifugation (3000× g, 5 m) and washed three times with YNB complete (1.7 g yeast
nitrogen base without amino acids or ammonium sulfate, 5 g ammonium sulfate per liter, pH 5.0)
without glucose (for starvation) and without supplementation, unless otherwise noted. Cells were
resuspended at an OD600 of 75 in YNB for 2− 3h for glucose starvation. Reaction mixes consisted
of 250 µL of YNB, 200 µL of cells (75 OD) and 50 µL of [3H]-FLC (1/100 dilution of stock). The
resulting [3H]-FLC concentration is 50 nM (0.015 µg/mL), which is significantly below the MIC for
all strains. Samples (100 µL) were removed at various time points and placed into 5 ml stop solution
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(YNB +20 mM [6 µg/mL] FLC), filtered on glass fibre filters (24 mm GF/C; Whatman; Kent, UK)
pre-wetted with stop solution and washed with 5 ml of stop solution. Filters were transferred to 20 ml
scintillation vials. Scintillation cocktail (Ecoscint XR, National Diagnostics, Atlanta GA) was added
(15 ml) and the radioactivity associated with the filter was measured with a liquid scintillation analyzer
(Tri-Carb 2800 TR; Perkin Elmer; Waltham, MA) and normalized to CPM/1 × 108 cells. Rate of
[3H]-FLC uptake was determined by incubating samples in the presence of increasing concentrations
of unlabeled FLC (unless otherwise noted) and samples were analyzed for [3H]-FLC accumulation at
designated time points.
Computational methods
Numerical simulations of a theoretical community model were obtained using Matlab’s differential
equation solvers to generate the season-by-season dynamical map Φ(f). Differential equations were
parameterised using data from C. albicans and C. glabrata, as detailed in the supplementary.
To determine tipping points, we sought significant increases in between-replicated variation (BRV)
defined as follows. If F = {fj}nj=1 is the set of observed C. albicans frequencies, expressed as values
between zero and one (although some figures express this as a percentage), the set of between-
replicate differences is then {|fj − fk|}nj,k=1,j>k and mean BRV is the mean of this set; note, this is
one form of set radius. As the frequency of C. glabrata is Gj = 1−fj and Gj−Gk = 1−fj−(1−fk) =
fk − fj , C. glabrata frequency data has the same between-replicate differences as C.albicans.
Kernel density estimates were obtained for distributions of BRV values (Figure 4(a)) using a
kernel estimation algorithm implemented in Matlab (64). To test for significant season-by-season
differences in BRV, BRVn and BRVn+1 observed at seasons n and n+1, we applied linear regression
to test (with p < 0.001) against the null hypothesis of a constant mean BRV between those seasons,
testing for a non-zero slope parameter from the regression. This is written ∆BRV and this change
was found to be largest for season 6 of treatment γ (Figure 4(b)).
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary
linked to this article.
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Data availability statement
All experimental data generated during this study can be found at https://doi.org/10.24378/exe.345.
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Figure 1: a) Lab data: C. albicans and C. glabrata are inoculated at 50-50 proportions into growth
in SC media supplemented with 0.1% glucose and propagated in the presence of fluconazole for 2
seasons, the C. albicans frequency subsequently decreases. After 2 seasons, fluconazole is withdrawn
and C. albicans recovers. When fluconazole is later re-applied for 3 seasons C. albicans again decreases
in frequency, and so the cycle repeats. (Grey boxes mark seasons undergoing fluconazole treatment,
error bars are mean ± 95% CI, n = 3, raw data shown.) b) Lab data: the initial C. albicans frequency
(f) on the x-axis versus the final frequency each season obtained using the laboratory microcosm
on the y-axis, aka Φ(f) (four exemplars are shown; error bars are mean ± 95% CI, n = 3; glucose
and fluconazole given in the legend, SC denotes synthetic complete media). c) Theoretical example:
how to read Φ(f) to understand dynamics: starting at timepoint 0, the dynamics follow Φon while
treatment proceeds, it then follows Φoff when treatment stops. The sequence of treatments here
is (on,on,on,on,off,on,off,on,on,off). The right plot shows how C. albicans reversibly increases and
decreases in frequency according to whether drug is used (solid dot) or not (open circle).
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Figure 2: Population dynamics theory states that one can deduce multi-season frequency dynamics
from the ‘cobweb diagram’ determined from the initial C. albicans frequency plotted versus the final
frequency each season. a): Φon lies below the diagonal so C. glabrata outcompetes C. albicans. b)
Φoff lies above the diagonal line of equal frequencies, so C. albicans outcompetes C. glabrata. c) Φoff
is such that there exist a special frequency, fc, which lies on the diagonal line and Φoff(f) > f for
0 < f < fc while Φoff(f) < f for fc < f < 1, this is a stable coexistence state. d) Φoff is such that
there exist a special frequency, fu, which lies on the diagonal line and Φoff(f) < f for 0 < f < fu
while Φoff(f) > f for fu < f < 1. In this case either species can dominate depending on their initial
frequencies: if the initial frequency of C. albicans is smaller than fu then C. albicans loses out in
competition to C. glabrata, otherwise C. glabrata loses out; this is ‘bistable exclusion’. e) A theoretical
example of a 3-season treatment, which stops short of the tipping point (marked ’tip’) with seasons
4-9 continuing without the drug being applied. f) A theoretical example of a 4-season treatment
which goes beyond the tipping point, causing the divergence in trajectories following drug withdrawal
cause by the tipping point as shown in (g). h) This is a theoretical two-dimensional dose-response
mosaic, it describes the equilibrium outcome of competition in the Candida community as glucose
and fluconazole are varied. C. albicans wins the competition inside orange squares, C. glabrata wins
inside the blue squares and bistable exclusion occurs in the grey squares. Drug on-off treatments
that encounter the latter may exhibit tipping (e.g. ABAB, FEFE and CDCD treatment sequences),
treatments that stay inside the former will exhibit reversible resistance (e.g. an FBFB sequence). i)
theoretical Φ functions at points A-F in the dose response mosaic, with dots highlighting the location
of the special frequency fu for each Φ that crosses the diagonal.
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Figure 3: The dose-response mosaic shows tipping points are encountered in many ways, for example
by varying glucose concentration (see Supporting Fig. S10 for details) or as fluconazole concentration
is varied (a). In (a) four, fixed-dose treatments start on season 5 and end on season 12 (grey box) at
a 0.95% (by volume) glucose dose. First, the community converges towards C. albicans domination
in the absence of drug (orange dots). C. glabrata starts to dominate as drug is applied, but it rescinds
when treatment ends (brown dots) and the community returns to its pre-treatment composition and
then continues towards C. albicans dominance with more seasons. However, a tipping point appears
at just high-enough fluconazole dose (dark blue dots) whereby the post-treatment trajectory diverges
from the previous outcome (at a slightly lower drug dose) and C. albicans is lost as the seasons pass.
Royal blue dots show trajectories at dosages well above the tipping point. (b) Introducing additive
stochastic noise to simulations from (a) shows that replicate trajectories diverge at the tipping point,
creating large variations between frequency trajectories that had identical drug dosage regimes and
initial Candida frequencies. A signature we can seek in empirical data: between replicate variation
(BRV) spikes at the tipping point (c), causing a large season-by-season change in BRV (∆BRV here
taken to be the mean change in standard deviation) that is significantly positive at the tipping point
(d).
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Figure 4: a) Three laboratory treatments with different dynamics: treatments α (red) and γ (black)
withdraw fluconazole but β (blue) keeps it at constant levels (dosages represented as circle sizes). The
laboratory experimental trajectories of treatments are shown in (b) and the corresponding between-
replicate variation (BRV) is shown in (c) as indicated by the kernel density estimate of the distribution
of final-season C. albicans frequency differences (48 replicates for α, 96 for β and 55 for γ). The
trajectories of treatments α and β have low BRV in species frequencies at all times whereas γ
has high BRV at the end of treatment. The trajectories show why: community dynamics for β
maintain steady-state and C.albicans sweeps through the community during treatment α following
drug withdrawal. However, in γ trajectories of different replicates vary markedly beyond season 6
whereby either species can dominate by season 14, despite all replicates having close to 50-50 initial
composition (Supporting Fig. S11 has additional data). d) Data from the Candida community shows
mean BRV increases significantly, approximately 8-fold for treatment γ on season 6. Treatments α
and β also have significant increases on occasion, but by no more than 3-fold. Taking a conservative
Bonferroni-corrected significance at the level p < 0.001 in an F-test using linear regression (see
Methods), significant changes in mean BRV are shown in (e) as circled dots. The largest increase
(approximately 8-fold) is significant and occurs in treatment γ on season 7 (error bars explained in
legend).
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